EGFR and hereditary breast carcinoma: Nevertheless, we were unable to identify, at the time of writing, studies that have evaluated EGFR as a prognostic marker in familial breast tumours, or the benefits of EGFR-targeted tyrosine kinase inhibitors, specifically in clinical familial breast cancer studies.